CN112125955A - 一种活性肽、活性肽组合物及其在制备具有抗uv导致皮肤细胞氧化损伤作用的产品中的应用 - Google Patents
一种活性肽、活性肽组合物及其在制备具有抗uv导致皮肤细胞氧化损伤作用的产品中的应用 Download PDFInfo
- Publication number
- CN112125955A CN112125955A CN202011088799.6A CN202011088799A CN112125955A CN 112125955 A CN112125955 A CN 112125955A CN 202011088799 A CN202011088799 A CN 202011088799A CN 112125955 A CN112125955 A CN 112125955A
- Authority
- CN
- China
- Prior art keywords
- active peptide
- seq
- oligopeptide
- active
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 106
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000000694 effects Effects 0.000 title claims abstract description 25
- 230000004792 oxidative damage Effects 0.000 title claims abstract description 19
- 210000004927 skin cell Anatomy 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 210000003491 skin Anatomy 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 239000002537 cosmetic Substances 0.000 claims description 15
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003796 beauty Effects 0.000 abstract description 3
- 241000881711 Acipenser sturio Species 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 36
- 239000000047 product Substances 0.000 description 27
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 23
- 101100488850 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) yop-1 gene Proteins 0.000 description 21
- 235000015067 sauces Nutrition 0.000 description 19
- 230000006907 apoptotic process Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 11
- 230000005855 radiation Effects 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 241000235342 Saccharomycetes Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000012138 yeast extract Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 206010051246 Photodermatosis Diseases 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000008845 photoaging Effects 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000007664 blowing Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- -1 lipid peroxide Chemical class 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SIRPVCUJLVXZPW-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-imidazol-5-yl)propanoic acid Chemical class C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CNC=N1 SIRPVCUJLVXZPW-IBGZPJMESA-N 0.000 description 2
- QEPWHIXHJNNGLU-KRWDZBQOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 QEPWHIXHJNNGLU-KRWDZBQOSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 101710108790 Stromelysin-1 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- JZTKZVJMSCONAK-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-hydroxypropanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CO)C(O)=O)C3=CC=CC=C3C2=C1 JZTKZVJMSCONAK-INIZCTEOSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- AAAFQLPJNOITCL-SFHVURJKSA-N 9h-fluoren-9-ylmethyl n-[(2s)-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C([C@@H](C=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 AAAFQLPJNOITCL-SFHVURJKSA-N 0.000 description 1
- 238000012406 Annexin V-FITC/PI double staining Methods 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- VLMNBMFYRMGEMB-QWRGUYRKSA-N Lys-His-Gly Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CNC=N1 VLMNBMFYRMGEMB-QWRGUYRKSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- AKJAKCBHLJGRBU-JYJNAYRXSA-N Phe-Glu-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N AKJAKCBHLJGRBU-JYJNAYRXSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002774 effect on peptide Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 231100000589 photocarcinogenesis Toxicity 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及生物医学技术领域,具体公开了一种活性肽、活性肽组合物及其在制备具有抗UV导致皮肤细胞氧化损伤作用的美容产品中的应用。所述活性肽的氨基酸序列如SEQ ID No.1或SEQ ID No.2所示。所述的活性肽组合物,包含SEQ ID No.1和SEQ ID No.2所示的活性肽。本发明所述的活性肽或活性肽组合物具有抗氧化损伤作用;尤其是具有抗UV导致皮肤细胞氧化损伤作用。
Description
技术领域
本发明涉及生物医学技术领域,具体涉及一种活性肽、活性肽组合物及其在制备具有抗UV导致皮肤细胞氧化损伤作用的产品中的应用。
背景技术
皮肤衰老分为内源性老化和外源性老化,外源性老化由外界环境因素或生活方式等原因引起。其中太阳中的紫外线辐照是其形成的主要因素,所以外源性老化又称为光老化。近几十年来,由于臭氧层的破坏、过度日光浴等原因使人体暴露部位的皮肤衰老约80%以上属于光老化。紫外线辐照可通过产生活性氧(ROS)、引起炎性因子分泌、诱导DNA损伤及细胞凋亡等造成皮肤急、慢性损害。急性损害包括红斑、水疱、炎症等,而慢性光暴露最终会导致光老化、光致癌等。
中波紫外线(Ultraviolet B,UVB)会作用于皮肤中的各种光敏物质,诱导产生脂质过氧化物为主的氧自由基(ROS),破坏皮肤自身的抗氧化体系,使抗氧化酶活性下降并造成脂质过氧化物堆积。UVB造成的氧化应激还可引发部分细胞内信号传导,通过核转录因子NF-κB激活下游MMP等基因的表达,特异性降解细胞外基质,出现光老化的皮损。UVB辐照会诱导正常人皮肤真皮抑制性T细胞出现,辐照部位细胞NO及TNF-α分泌增加;UVB辐照也会诱导成纤维细胞IL-1(IL-1α和IL-1β)促进细胞MMP-1表达增加,促进光老化。
天然产物小分子化合物对皮肤具有光保护作用,中药含有的肽类、小分子化合物具有抗氧化损伤、清除自由基、抗炎等多种生物活性,受到临床的广泛重视和应用。因此,开发更多的结构新颖的具有上述任一生物活性的肽类、小分子化合物具有重要的应用价值。
发明内容
鉴于此,本发明首先提供一种全新结构的活性肽,经进一步研究表明,该活性肽具有抗氧化损伤作用;尤其是具有抗UV导致皮肤细胞氧化损伤作用。
此外,本发明还提供一种全新的活性肽组合物,该活性肽组合物能发挥协同抗氧化损伤作用,尤其是能发挥协同抗UV导致皮肤细胞氧化损伤作用。
另外,本发明还提供了一种上述活性肽或活性肽组合物在制备美容产品或护肤产品中的应用。
本发明的详细技术方案如下:
本发明提供了一种活性肽,所述活性肽的氨基酸序列如SEQ ID No.1或SEQ IDNo.2所示。
在本发明中,将SEQ ID No.1所示的活性肽命名为酵母菌寡肽-β;将SEQ ID No.2所示的活性肽命名为鲟鱼籽酱寡肽-α。其中,酵母菌寡肽-β简写为JMOP-β,鲟鱼籽酱寡肽-α简写为XYOP-α。
酵母菌寡肽-β的氨基酸序列为Lys-His-Gly-Glu-Leu(KHGEL);其结构式如式(Ⅰ)所示:
鲟鱼籽酱寡肽-α的氨基酸序列为Phe-Glu-His-Ser-Gly(FEHSG);其结构式如式(Ⅱ)所示:
本发明还提供了一种活性肽组合物,包含SEQ ID No.1和SEQ ID No.2所示的活性肽。
本发明所述的酵母菌寡肽-β和鲟鱼籽酱寡肽-α可以从酵母菌和鲟鱼籽中分离纯化得到或通过人工合成方法得到。
可选的,所述从酵母菌、鲟鱼籽中分离得到包括:
将酵母菌提取物或鲟鱼籽与有机溶剂混合,萃取得到水相层,经过真空低温冻干后经色谱法分离及HPLC制备得到所述抗UV导致皮肤细胞氧化损伤作用的活性化合物。
进一步可选的,所述酵母菌提取物或鲟鱼籽与所述有机溶剂的体积比为1:(2.5-10)。
进一步可选的,所述酵母菌提取物或鲟鱼籽与所述有机溶剂混合还包括,所述酵母菌提取物或鲟鱼籽、所述有机溶剂与水混合。在本发明中,酵母菌提取物或鲟鱼籽和有机溶剂的混合液中加入水更有利于萃取的进行。
具体的,可以但不限于为,100g酵母菌提取物或鲟鱼籽、700mL乙酸乙酯和3000mL水混合,萃取得水层,并重复3次,经过真空低温冻干后经色谱法分离及HPLC制备得到所述酵母菌寡肽-β或鲟鱼籽酱寡肽-α。
在本发明中,所述酵母菌寡肽-β和鲟鱼籽酱寡肽-α可以从酵母菌提取物或鲟鱼籽中制备得到,为酵母菌寡肽-β和鲟鱼籽酱寡肽-α的制备方法提供了一个新的途径。
优选地,SEQ ID No.1和SEQ ID No.2所示的活性肽的摩尔比为1~5:1~5。
进一步优选地,SEQ ID No.1和SEQ ID No.2所示的活性肽的摩尔比为1~3:1~3。
最优选地,SEQ ID No.1和SEQ ID No.2所示的活性肽的摩尔比为1:1。
本发明还提供一种上述活性肽或活性肽组合物作为抗氧化剂或抗炎药物的应用。
优选地,所述的抗氧化剂为抗UV导致皮肤细胞氧化损伤的抗氧化剂。
本发明还提供一种上述活性肽或活性肽组合物在制备美容产品、护肤产品、食品或药物中的应用。
优选地,所述的美容产品、护肤产品、食品或药物为具有抗氧化作用或抗炎作用的美容产品、护肤产品、食品或药物。
优选地,所述的美容产品、护肤产品、食品或药物为具有抗UV导致皮肤细胞氧化损伤作用的美容产品、护肤产品、食品或药物。
本发明还提供了一种组合物,其包括载体以及负载在所述载体上的上述活性肽或活性肽组合物。
可选的,所述载体包括溶剂、聚合物和脂质体中的至少一种。更进一步可选的,所述溶剂包括但不限于水、生理盐水,以及其他非水性溶剂。具体的,所述聚合物可以但不限于为聚赖氨酸、聚乙烯亚胺及其改性物、壳聚糖、聚乳酸、明胶。具体的,所述脂质体可以但不限于为胆固醇、豆卵磷脂、蛋黄卵磷脂。进一步可选的,所述载体还包括稀释剂和赋形剂中的一种或多种。进一步可选的,所述稀释剂包括淀粉类、糖类、纤维素类和无机盐中的一种或多种。进一步可选的,所述赋形剂包括片剂中的黏合剂、填充剂、润滑剂,半固体制剂软膏剂、霜剂中的基质部分,液体制剂中的防腐剂、抗氧剂、矫味剂、芳香剂、助溶剂、乳化剂、着色剂中的至少一种。
可选的,所述组合物中所述活性肽或活性肽组合物的质量分数为5%-75%。进一步可选的,所述组合物中活性肽或活性肽组合物的质量分数为10%-90%、15%-85%或30%-80%。
可选的,所述组合物还可以包括第二活性成分。所述第二活性成分根据所述组合物的用途进行选择,在此不作限定。具体的,可以但不限于,当所述组合物用于抗炎时,所述第二活性成分具有抗炎活性,可选的,所述第二活性成分包括维生素C、维生素E、辅酶Q、谷胱甘肽、胡萝卜素和甜菜碱中的至少一种;当所述组合物用于抗炎以及抗炎时,所述第二活性成分至少具有抗炎活性。
进一步可选的,所述组合物中所述第二活性成分的质量分数为1%-70%。
所述食品包括保健品。在本发明中,所述活性肽或活性肽组合物作为食品添加剂加入至食品,甚至是保健品中,作为抗氧化的有效成分。
可选的,所述食品和所述药物的形式包括片剂、胶囊、粉剂、颗粒剂、丸剂、糖浆剂、溶液剂、混悬剂或气雾剂。
可选的,所述药物为化学类药物和生物药物中的至少一种。进一步可选的,所述生物药物为多肽类药物、蛋白药物和基因药物中的一种或多种。
可选的,所述保健品的形式包括、凝胶状或水剂状。
进一步可选的,所述保健品还包括辅料基质,所述辅料基质包括单糖、寡糖、多糖、氨基酸、防腐剂、pH调节剂、抗炎助剂。
可选的,所述的美容产品包括化妆品,所述的护肤产品包括护肤品。所述的化妆品和护肤品包括保乳、霜。在本发明中,所述活性肽或活性肽组合物为化妆品或护肤品添加剂加入至化妆品或护肤品中,作为抗氧化的有效成分。
有益效果:(1)本发明提供了全新结构的活性肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α。试验结果表明活性肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α可以明显提高UVB辐照HaCaT细胞后的细胞活性,其作用与维生素C相当,甚至高于维生素C,这说明本发明全新结构的酵母菌寡肽-β和鲟鱼籽酱寡肽-α具有优异的抗氧化作用;尤其是具有优异的抗UV导致皮肤细胞氧化损伤作用。进一步研究表明,将肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α混合后,其对UVB辐照HaCaT细胞后的细胞活性提升的更加明显,这说明肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α混合发挥了协同抗氧化作用。更进一步地,通过建立体外抗UVB诱导的HaCaT细胞氧化损伤的实验模型进行试验,发现酵母菌寡肽-β和鲟鱼籽酱寡肽-α组合后可以通过降低细胞内UVB诱导的ROS含量降低、炎性因子分泌减少,降低细胞凋亡,达到抗氧化损伤目的。(2)由于活性肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α具有优异的抗氧化活性,因此,活性肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α可以作为抗氧化剂使用,在美容产品、护肤产品、食品或药物中具有广泛的应用前景。(3)本发明所述的全新的活性肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α可以采用从酵母菌和鲟鱼籽中分离得到,来源丰富;且活性肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α均为为短肽,制备工艺简单、操作方便,制得的抗氧化活性肽纯度高,有利于其在食品、药品、保健品和化妆品中的应用。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例的附图,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是JMOP-β的质谱图。
图2是JMOP-β的高效液相色谱测定结果图。
图3是XYOP-α的质谱图。
图4是XYOP-α的高效液相色谱测定结果图。
图5是XYOP-α、JMOP-β对HaCaT细胞毒性测试结果图。
图6是YOP-1抑制UVB辐照HaCaT细胞诱发的氧化应激及炎症反应实验结果图。
图7是YOP-1抑制UVB辐照导致的HaCaT细胞凋亡实验结果图。
图8YOP-1抑制因UVB辐照导致的MMPs高表达及ATM-p53通路激活实验结果图。
具体实施方式
下面将结合实施例对本发明技术方案进行清楚、完整地描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1活性肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α的分离
将100g酵母菌用2000mL乙酸乙酯和3000mL水混合均匀,静置后萃取得到水相层,多次重复萃取过程,将水相层进行真空低温冻干,再经制备型HPLC进行制备分离,得到活性肽酵母菌寡肽-β(JMOP-β)。
将100g鲟鱼籽用2000mL乙酸乙酯和3000mL水混合均匀,静置后萃取得到水相层,多次重复萃取过程,将水相层进行真空低温冻干,再经制备型HPLC进行制备分离,得到活性肽鲟鱼籽酱寡肽-α(XYOP-α)。
上述制备型HPLC的制备条件为:以0.1%三氟乙酸水溶液为流动相A,以0.1%三氟乙酸的乙腈溶液为流动相A,流动相A:流动相B=70:30,测波长为280μm。由图2和图4可以看出活性肽酵母菌寡肽-β(JMOP-β)和活性肽鲟鱼籽酱寡肽-α(XYOP-α)出峰时间分别为11.4min和10.0min。
将分离得到的活性肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α利用质谱和高效液相色谱对其进行测定,其中质谱测定条件为ESI正离子模式毛细管电压3kV,锥孔电压50V,萃取电压5V,脱溶剂温度350℃,雾化气流350L/h;高效液相色谱测定条件为采用Boston GreenODS-AQ色谱柱(250*4.6mm),以0.1%三氟乙酸水溶液为流动相A,以0.1%三氟乙酸的乙腈溶液为流动相A,流动相A:流动相B=70:30,流速为1mL/min,检测波长为280μm,进样量10μL。
从图1和图3中显示的JMOP-β和XYOP-α的质谱图可以确定,活性肽酵母菌寡肽-β(JMOP-β)的氨基酸序列为Lys-His-Gly-Glu-Leu(KHGEL),活性肽鲟鱼籽酱寡肽-α(XYOP-α)的氨基酸序列为Phe-Glu-His-Ser-Gly(FEHSG)。
实施例2活性肽酵母菌寡肽-β和鲟鱼籽酱寡肽-α的化学合成
(1)取100mg Fmoc-Lys Wang Resin置于固相合成管中,加入N,N-二甲基甲酰胺(DMF)后静置使树脂充分溶胀,滤去溶剂,再加入哌啶DMF溶液,振荡后滤出溶剂。将Fmoc-Lys-OH、1-羟基苯并三唑、O-苯并三氮唑-四甲基脲六氟磷酸酯溶于DMF中,在加入N,N-二异丙基乙胺混匀后避光后即已被活化,并加入树脂中,室温下氮气吹动搅拌,经抽滤后用DMF和二氯甲烷依次洗涤并抽干溶剂。重复上述步骤,将活化好的Fmoc-His-OH、Fmoc-Gly-OH、Fmoc-Glu-OH、Fmoc-Leu-OH依次加入树脂中,室温下氮气吹动搅拌,反应完全后洗涤树脂,将得到的滤液进行旋蒸并得到沉淀,经冷冻干燥后即可得到活性肽酵母菌寡肽-β(JMOP-β),其氨基酸序列为Lys-His-Gly-Glu-Leu。
(2)取100mg Fmoc-Phe Wang Resin置于固相合成管中,加入N,N-二甲基甲酰胺(DMF)后静置使树脂充分溶胀,滤去溶剂,再加入哌啶DMF溶液,振荡后滤出溶剂。将Fmoc-Phe-OH、1-羟基苯并三唑、O-苯并三氮唑-四甲基脲六氟磷酸酯溶于DMF中,在加入N,N-二异丙基乙胺混匀后避光后即已被活化,并加入树脂中,室温下氮气吹动搅拌,经抽滤后用DMF和二氯甲烷依次洗涤并抽干溶剂。重复上述步骤,将活化好的Fmoc-Glu-OH、Fmoc-His-OH、Fmoc-Ser-OH、Fmoc-Gly-OH依次加入树脂中,室温下氮气吹动搅拌,反应完全后洗涤树脂,将得到的滤液进行旋蒸并得到沉淀,经冷冻干燥后即可得到活性肽鲟鱼籽酱寡肽-α(XYOP-α),其氨基酸序列为Phe-Glu-His-Ser-Gly。
效果实验例1
为了评估本发明上活性肽和活性肽组合物的活性化合物的效果,进行如下效果实施例。
永生化角质形成细胞系HaCaT细胞培养于细胞培养箱中,37℃、5%CO2(DMEM培养基)。UVB的辐照强度为7.15×10-5J/cm2,辐照光源与细胞相距15cm。辐照时吸去各组培养细胞培养液,PBS冲洗2次,再加入少量覆盖底面避免干燥。培养板于室温水浴下照光以避免辐照后过热。辐照后再弃去PBS,重新加入DMEM培养基或含活性肽或活性肽组合物培养基继续培养24h。CCK8方法检测细胞活力,收集细胞和培养液。YOP-1为XYOP-α及JMOP-β的等摩尔比例组合物。
在活性肽和活性肽组合物及对HaCaT细胞活力的影响试验中,将实验分为6组:正常对照组(Control);UVB辐照组;XYOP-α组(UVB辐照+XYOP-α20μM);JMOP-β组(UVB辐照+JMOP-β20μM)、YOP-1组(UVB辐照+YOP-120μM)、阳性对照组(UVB辐照+Vitamin C 20μM)。每个处理条件3个复孔,重复实验3次。正常对照组不接受UVB辐照,UVB辐照组、XYOP-α组、JMOP-β组、YOP-1组以及阳性对照组则分别接受UVB辐照。测试结果见表1。
表1活性肽和活性肽组合物及对HaCaT细胞活力的影响
当p<0.05时认为差异有统计学意义(#Vs Control,*Vs UVB)
从表1数据中可以看出,活性肽酵母菌寡肽-β(JMOP-β)和活性肽鲟鱼籽酱寡肽-α(XYOP-α)对经UVB辐照后的HaCaT细胞活力均有明显提升,且活性肽鲟鱼籽酱寡肽-α(XYOP-α)的提升幅度要大于Vitamin C。这说明活性肽酵母菌寡肽-β(JMOP-β)和活性肽鲟鱼籽酱寡肽-α(XYOP-α)均具有抗氧化活性,其中活性肽鲟鱼籽酱寡肽-α(XYOP-α)的抗氧化活性要大于Vitamin C。
进一步地,从表1数据中还可以看出,YOP-1组对经UVB辐照后的HaCaT细胞活力提升得最显著,分别大于JMOP-β组和XYOP-α组;这说明将活性肽酵母菌寡肽-β(JMOP-β)和活性肽鲟鱼籽酱寡肽-α(XYOP-α)组合后形成的组合活性肽,其能发挥协同抗氧化作用。
效果实验例2
参照效果实验例1的实验方法,将实验分为4组:正常对照组;UVB辐照组;YOP-1-L组(UVB辐照+YOP-1 10μM);YOP-1-H组(UVB辐照+YOP-1 50μM)。每个处理条件3个复孔,重复实验3次。正常对照组不接受UVB辐照,UVB辐照组、YOP-1-L组、YOP-1-H组则分别接受UVB辐照。
HaCaT细胞按实验设计处理后,收集细胞培养液;参考ELISA试剂盒操作说明书检测IL-6、IL-1β、NO、TNF-α的分泌量。
HaCaT细胞按实验设计处理后,收集细胞,在室温下于2000g离心3min。细胞在预冷1×PBS中悬浮,2000g离心3min,洗涤细胞。Annexin V-FITC/PI双染色实验按照制造商的说明进行。流式细胞仪检测细胞凋亡,所有实验至少重复3次。
HaCaT细胞按实验设计处理后,收集细胞,用预冷的PBS洗2次,加入50μL细胞裂解液,4℃静置30min。10000r/min离心15min,取上清提取总蛋白,用BCA法进行蛋白定量。总蛋白经SDS-PAGE分离后,转移至PVDF膜上。用5%脱脂奶粉室温封闭2h。随后加入一抗,4℃轻摇过夜,用TBST洗3次,加入相应的二抗,室温孵育1h,漂洗3次。
结果如下:
如图5所示,XYOP-α及JMOP-β的细胞毒性结果显示XYOP-α及JMOP-β在2.5mM浓度时对HaCaT细胞没有显著性细胞毒。进一步的实验结果显示,XYOP-α及JMOP-β(20μM)均能抑制UVB辐照导致的细胞活力降低。其中,XYOP-α及JMOP-β均能显著抑制UVB辐照导致的细胞活力降低。
如图6a~c所示,与Control组相比,UVB辐照使HaCaT细胞内ROS含量增加,而YOP-1使UVB辐照诱发的ROS降低。ROS水平增加会进一步导致HaCaT细胞凋亡,线粒体介导的凋亡途径可由多种因素触发,如线粒体功能障碍。线粒体膜电位(ΔΨm)下降可导致细胞色素c(Cyt c)从线粒体释放到细胞质中。与Control组相比,UVB辐照使细胞ΔΨm下降增加;线粒体Cyt c含量减少,而胞浆中Cyt c含量增加,说明UVB辐照导致HaCaT细胞氧化损伤、凋亡。而YOP-1抑制了UVB辐照诱发的ΔΨm下降及线粒体Cyt c的释放。
如图6d所示,UVB辐照使HaCaT细胞IL-6、IL-1β及TNF-α分泌增加,说明UVB辐照诱发HaCaT细胞严重的炎症反应。而YOP-1(50μM)使UVB辐照诱发的HaCaT细胞IL-6、IL-1β及TNF-α分泌降低。YOP-1可显著降低UVB辐照诱发的HaCaT细胞炎性细胞因子分泌。
如图7所示,UVB辐照可诱发DNA损伤及氧化应激进而导致角质细胞凋亡,最终,加重皮肤损伤。UVB辐照使HaCaT细胞凋亡增加。经YOP-1处理后HaCaT细胞凋亡率明显下降。我们推测,YOP-1可通过减轻UVB辐照诱发的HaCaT细胞凋亡以减轻其对皮肤造成的损伤。
UVB激活MMPs的分泌是皮肤受损、老化的标志之一。为了研究YOP-1对UVB诱导的MMPs表达的影响,我们检测了YOP-1对UVB诱导的MMPs分泌的影响。结果显示,UVB辐照使HaCaT细胞MMP-1、MMP-3表达均显著增加,而YOP-1可抑制UVB诱导的MMP-1和MMP-3表达。ELISA结果与Western blotting结果类似,UVB辐照HaCaT细胞后,MMP-1和-3分泌增加。而YOP-1降低UVB辐照诱导的HaCaT细胞MMP-1和-3分泌(见图8a和8b)。
研究报道,UVB辐照会引起DNA损伤,进而激活ATM引起细胞周期阻滞、DNA修复或凋亡。UVB辐照可使ATM、p-ATM及其下游p53表达上调,而YOP-1处理显著抑制了ATM、p-ATM及p53的表达上调(见图8c)。
ROS水平增加会进一步导致HaCaT细胞氧化损伤、凋亡,线粒体介导的凋亡途径可由多种因素触发,包括Bcl-2家族蛋白的表达,而Bcl-2家族蛋白可影响线粒体膜通透性。而线粒体功能障碍,如线粒体膜电位(ΔΨm)下降可导致细胞色素c(Cyt c)从线粒体释放到细胞质中。此外,p53可反式激活多种促凋亡的蛋白质,如Bax、Bid。在本研究中,UVB辐照可显著上调Bax、Bid的表达,抑制Bcl-2、Bcl-xL表达,而YOP-1处理显著抑制了Bax和Bid的表达,促进了Bcl-2、Bcl-xL表达,表明YOP-1通过抑制p53的活性来调控促凋亡蛋白的反式激活,这些结果进一步提示UVB通过ATM-p53轴引起HaCaT细胞凋亡,而YOP-1可阻断这一过程(见图8d)。
以上所揭露的仅为本发明较佳实施例而已,当然不能以此来限定本发明之权利范围,本领域普通技术人员可以理解实现上述实施例的全部或部分流程,并依本发明权利要求所作的等同变化,仍属于发明所涵盖的范围。
序列表
<110> 深圳海创生物科技有限公司
<120> 一种活性肽、活性肽组合物及其在制备具有抗UV导致皮肤细胞氧化损伤作用的产品中的应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 5
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Lys His Gly Glu Leu
1 5
<210> 2
<211> 5
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Phe Glu His Ser Gly
1 5
Claims (10)
1.一种活性肽,其特征在于,所述活性肽的氨基酸序列如SEQ ID No.1或SEQ ID No.2所示。
2.一种活性肽组合物,其特征在于,包含SEQ ID No.1和SEQ ID No.2所示的活性肽。
3.根据权利要求2所述的活性肽组合物,其特征在于,SEQ ID No.1和SEQ ID No.2所示的活性肽的摩尔比为1~5:1~5。
4.根据权利要求3所述的活性肽组合物,其特征在于,SEQ ID No.1和SEQ ID No.2所示的活性肽的摩尔比为1~3:1~3。
5.根据权利要求4所述的活性肽组合物,其特征在于,SEQ ID No.1和SEQ ID No.2所示的活性肽的摩尔比为1:1。
6.权利要求1~5任一项所述的活性肽或活性肽组合物作为抗氧化剂或抗炎药物的应用。
7.权利要求1~5任一项所述的活性肽或活性肽组合物在制备美容产品、护肤产品、食品或药物中的应用。
8.根据权利要求7所述的应用,其特征在于,所述的美容产品、护肤产品、食品或药物为具有抗氧化作用或抗炎作用的美容产品、护肤产品、食品或药物。
9.根据权利要求7所述的应用,其特征在于,所述的美容产品、护肤产品、食品或药物为具有抗UV导致皮肤细胞氧化损伤作用的美容产品、护肤产品、食品或药物。
10.一种组合物,其特征在于,包括载体以及负载在所述载体上的权利要求1~5任一项所述的活性肽或活性肽组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011088799.6A CN112125955A (zh) | 2020-10-13 | 2020-10-13 | 一种活性肽、活性肽组合物及其在制备具有抗uv导致皮肤细胞氧化损伤作用的产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011088799.6A CN112125955A (zh) | 2020-10-13 | 2020-10-13 | 一种活性肽、活性肽组合物及其在制备具有抗uv导致皮肤细胞氧化损伤作用的产品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112125955A true CN112125955A (zh) | 2020-12-25 |
Family
ID=73853826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011088799.6A Pending CN112125955A (zh) | 2020-10-13 | 2020-10-13 | 一种活性肽、活性肽组合物及其在制备具有抗uv导致皮肤细胞氧化损伤作用的产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112125955A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113307851A (zh) * | 2021-06-11 | 2021-08-27 | 北京戴域生物技术有限公司 | 一种改善皮肤生理特性的活性肽与间充质干细胞外泌体在药品或化妆品中的应用 |
WO2024074845A1 (en) * | 2022-10-06 | 2024-04-11 | Shah Caviar Limited | Caviar polypeptides |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030143245A1 (en) * | 2001-10-26 | 2003-07-31 | University Of Tennessee Research Corporation | Multivalent streptococcal vaccine compositions and methods for use |
CN109438556A (zh) * | 2018-10-31 | 2019-03-08 | 深圳凯联健康生物科技有限公司 | 活性肽、重组载体、重组细胞、抗炎组合物及其制备方法和应用 |
CN109517033A (zh) * | 2018-10-31 | 2019-03-26 | 深圳凯联健康生物科技有限公司 | 活性肽、重组载体、重组细胞、抗炎组合物及其制备方法和应用 |
CN111269290A (zh) * | 2020-02-28 | 2020-06-12 | 江苏大学 | 一种鲟鱼抗炎肽的制备方法 |
-
2020
- 2020-10-13 CN CN202011088799.6A patent/CN112125955A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030143245A1 (en) * | 2001-10-26 | 2003-07-31 | University Of Tennessee Research Corporation | Multivalent streptococcal vaccine compositions and methods for use |
CN109438556A (zh) * | 2018-10-31 | 2019-03-08 | 深圳凯联健康生物科技有限公司 | 活性肽、重组载体、重组细胞、抗炎组合物及其制备方法和应用 |
CN109517033A (zh) * | 2018-10-31 | 2019-03-26 | 深圳凯联健康生物科技有限公司 | 活性肽、重组载体、重组细胞、抗炎组合物及其制备方法和应用 |
CN111269290A (zh) * | 2020-02-28 | 2020-06-12 | 江苏大学 | 一种鲟鱼抗炎肽的制备方法 |
Non-Patent Citations (4)
Title |
---|
JIE LIU ET AL.: ""LingZhi oligopeptides amino acid sequence analysis and anticancer potency evaluation"", 《RSC ADVANCES》 * |
JINGQUAN ZHAO ET AL.: ""Structural characterization of centipede oligopeptides and capability detection in human small cell lung carcinoma: inducing apoptosis"", 《RSC ADVANCES》 * |
MAN ZHENG ET AL.: ""Structural characterization and anti-inflammatory potency of Mesobuthus martensii Karsch oligopeptides in lipopolysaccharide (LPS)-induced RAW264.7 macrophages"", 《RSC ADVANCES》 * |
万细妹 等: ""河蚬酶解液抗氧化作用的研究"", 《江西农业大学学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113307851A (zh) * | 2021-06-11 | 2021-08-27 | 北京戴域生物技术有限公司 | 一种改善皮肤生理特性的活性肽与间充质干细胞外泌体在药品或化妆品中的应用 |
WO2024074845A1 (en) * | 2022-10-06 | 2024-04-11 | Shah Caviar Limited | Caviar polypeptides |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ko et al. | Protective effect of a novel antioxidative peptide purified from a marine Chlorella ellipsoidea protein against free radical-induced oxidative stress | |
CN112812150A (zh) | 一种活性环肽、活性环肽组合物及其在制备具有抗氧化或抗炎作用的产品中的应用 | |
JP2012530769A (ja) | モリンガ種の完全な種子の抽出物並びに化粧品組成物及び/又は皮膚科学的組成物におけるその使用 | |
CN112125955A (zh) | 一种活性肽、活性肽组合物及其在制备具有抗uv导致皮肤细胞氧化损伤作用的产品中的应用 | |
CN112898383A (zh) | 一种寡肽、活性肽组合物及其在制备具有抗炎作用的产品中的应用 | |
KR20170090690A (ko) | 미코스포린―유사 아미노산을 함유한 창상 치유용 피부 외용제 조성물 및 그 제조방법 | |
Joshi et al. | Anti-inflammatory properties of bioactive peptide derived from gastropod influenced by enzymatic hydrolysis | |
CN112979749A (zh) | 一种活性环肽、活性环肽组合物及其在制备具有抗氧化作用或抗衰老作用的产品中的应用 | |
KR101515073B1 (ko) | 트리신 포접체, 제조방법 및 이를 포함하는 항산화 및 항염증 조성물 | |
KR101440684B1 (ko) | 클로렐라 유래 항산화 활성을 갖는 펩티드 | |
KR101475609B1 (ko) | 억새꽃 추출물을 유효성분으로 함유하는 피부 미백용 조성물 | |
JP5770428B2 (ja) | 一重項酸素消去剤、並びに該一重項酸素消去剤を用いた皮膚外用剤及び化粧料 | |
KR100708779B1 (ko) | 리포좀으로 안정화 된 우렁쉥이 또는 멍게 외막 추출물을함유하는 피부 노화 억제 및 주름 개선 화장료 조성물 | |
CN112515997A (zh) | 一种具有舒缓抗炎作用的组合物及其应用 | |
KR101512064B1 (ko) | 알러지 성분이 제거된 분리정제봉독을 이용한 기능성 봉독 화장품 조성물의 제조방법 | |
CN112979490B (zh) | 一种化合物、组合物及其在制备具有抗氧化或抗炎作用的产品中的应用 | |
JP3496967B2 (ja) | 抗プラスミン剤 | |
WO2014198789A1 (fr) | Composition cosmétique à propriété photoprotectrice | |
EP4166145A1 (en) | Nerve growth promoter and method for producing same, internal preparation, medium additive, cell dilution additive, medium, cell dilution, antioxidant and method for producing same, external preparation, and wound treatment agent and method for producing same | |
KR101441190B1 (ko) | 비양나무 추출물을 포함하는 화장료 조성물 | |
JP6047793B2 (ja) | 酵素活性阻害剤 | |
JPH11147832A (ja) | 好中球エラスターゼ阻害剤 | |
Bibi et al. | Antidiabetic, anti-inflammatory and antioxidant activity of Artemisia Roxburghiana along with its qualitative and quantitative phytochemical Screening | |
CN109232715A (zh) | 一类抗氧化超短肽及其应用 | |
KR101510315B1 (ko) | 멜라닌 생성 억제 및 주름개선용 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201225 |